Advances in taxane therapy for metastatic breast cancer.
This session discussed the use of taxanes in metastatic breast cancer therapy. Taxane toxicities, the mechanism of action, and efficacy were covered. Hypersensitivity, bone marrow toxicity, and other toxicities were detailed as well.
D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects* / Q000627:therapeutic use; D001853:Bone Marrow / Q000187:drug effects; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000556:secondary; D002626:Chemistry, Pharmaceutical; D000077143:Docetaxel; D004342:Drug Hypersensitivity / Q000209:etiology; D006331:Heart Diseases / Q000139:chemically induced; D006801:Humans; D009325:Nausea / Q000139:chemically induced; D017239:Paclitaxel / Q000009:adverse effects* / Q000627:therapeutic use; D043823:Taxoids / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome; D014839:Vomiting / Q000139:chemically induced; D014883:Water-Electrolyte Imbalance / Q000139:chemically induced
D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel